---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Heterogeneity of treatment effect"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Heterogeneity of treatment effect. Topics: Himalayas-1 stratification factors, Liver metastases and overall survival in castration-resistant disease, Phase 1b landmark radiographic progression-free survival by prior therapy, Phase 1b safety in the broader post-ARPI population, and 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Himalayas-1 stratification factors

> “Randomization will be stratified by prior docetaxel use in the metastatic castration-sensitive prostate cancer (mCSPC) setting, prespecified control category (ARPI versus docetaxel), and presence of hepatic metastases”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-2.2.2.3-2"></a>

### Liver metastases and overall survival in castration-resistant disease

> “Men with liver metastases had the worst median OS (13.5 months).”
> “In summary, men with mCRPC treated with docetaxel who have liver metastases had worse OS duration than men with lung metastases.”

Source: [Halabi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872320/)

<a id="topic-2.2.2.3-3"></a>

### Phase 1b landmark radiographic progression-free survival by prior therapy

| Cohort (rinzimetostat 400 mg once daily plus darolutamide) | Landmark rPFS at 3, 4, and 5 months | Median follow-up |
| --- | --- | --- |
| Previously treated with abiraterone | “93%, 84%, and 84% at 3, 4, and 5 months” | “4.9 months” |
| Previously treated with AR inhibitors | “93%, 85%, and 85% at 3, 4, and 5 months” | “4.8 months” |

Source: [ORIC Pharmaceuticals first quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates/)

<a id="topic-2.2.2.3-4"></a>

### Phase 1b safety in the broader post-ARPI population

> “In a broader dataset of post-ARPI (androgen receptor pathway inhibitor) patients (n=72, inclusive of the post-abiraterone patients), the safety and tolerability profile was consistent with the post-abiraterone cohort.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-2.2.2.3-5"></a>

### Phase 1b ctDNA responses by androgen receptor genotype and partner agent

> “ctDNA molecular responses across a breadth of genotypes including AR mutations, AR amplified, AR wildtype”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Rapid and deep ctDNA responses across a breadth of AR mutations and other gene alterations, with 76% of patients (13/17) achieving >50% ctDNA reduction.”
> “PSA responses and ctDNA reductions were observed across all ORIC-944 dose levels and were also observed at comparable rates in combination with apalutamide or with darolutamide.”

Source: [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/)

<a id="topic-2.2.2.3-6"></a>

### Prior androgen receptor pathway inhibitor exposure and outcomes with an ARPI versus cabazitaxel

> “Prior ARPI exposure (in 37.7%) predicted inferior outcomes on ARPIs but not on cabazitaxel.”
> “A high baseline ctDNA fraction correlated with reduced rPFS and OS; plasma AR copy number status was not associated with outcomes, but PTEN alterations were linked with shorter OS (hazard ratio: 1.9, multivariable p = 0.02).”

Source: [Parekh et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41033927/)

<a id="topic-2.2.2.3-7"></a>

### Duration of response to the first androgen receptor pathway inhibitor

> “In patients who had a short response to the first ARPI for mCRPC (< twelve months), this sequence should be avoided because of known cross resistance and the availability of chemotherapy and PARP inhibitors (if a relevant mutation is present).”
> “In highly selected patients treated for more than 24 weeks with AAP, the sequence with enzalutamide showed some activity with a median rPFS of 8.1 months (95% CI: 6.1–8.3) and an unconfirmed PSA response rate of 27%”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.3-8"></a>

### Circulating tumor DNA fraction as a prognostic and predictive factor

> “Baseline circulating tumour DNA (ctDNA) fraction above the cohort median and on-treatment ctDNA increase were associated with shorter time to progression (HR = 2.38, P < 0.001; HR = 4.03, P < 0.001).”
> “ctDNA abundance was prognostic independent of clinical features, and holds promise as a stratification biomarker.”

Source: [Annala et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33836265/)

> “a low pretreatment circulating tumor DNA (ctDNA) fraction predicted a superior biochemical response (100% versus 58%, P = 0.0067)”

Source: [Kwan et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40425844/)

<a id="topic-2.2.2.3-9"></a>

### Outcomes by treatment received before castration resistance

> “In the overall population, median TTPD was 12.1 months and trended lower for patients who had received prior ARPi-only treatment.”
> “Overall median OS was 24.6 months and trended lower for patients who received prior ARPi only or both prior ARPi and taxane.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
